TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 10 Best Performing American Stocks in June 2026.

On July 6, 2026, TG Therapeutics, Inc. (NASDAQ:TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi in adults with treatment-resistant schizophrenia. The open-label study is designed to evaluate the efficacy and safety of Briumvi in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite standard-of-care antipsychotic treatment.

On June 23, Jefferies raised the firm’s price target on TG Therapeutics to $83 from $57 and kept a Buy rating on the shares. Jefferies said the Street “still underappreciates the significance” of Phase 1 subcutaneous Briumvi pharmacokinetic data as predictive of a Phase 3 outcome expected by year-end 2026 to early 2027. Jefferies also updated its model to be more bullish on the subcutaneous opportunity.

On June 9, TG Therapeutics announced topline Phase 1 data for Briumvi in patients with myasthenia gravis and the initiation of a Phase 2 trial evaluating Briumvi as maintenance therapy after induction with efgartigimod. At Week 24, 82% of patients achieved the Minimal Clinically Important Difference in MG-ADL, with a median time to MCID of 30 days, while mean MG-ADL improvement was 4.6 points. The Phase 2 trial is expected to enroll approximately 120 patients, with time to clinical worsening as the primary endpoint.

TG Therapeutics, Inc. (NASDAQ:TGTX) focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.